CTT PHARMACEUTICAL HOLDINGS, INC. purchased $112 of CTTH
CTT PHARMACEUTICAL HOLDINGS, INC. (CEO) purchased 1,800 shares of CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) at $0.06 on 2026-08-14.
How this was made
The 30-second read
Why it matters
The only new information is the CEO’s open-market purchase details (shares, price, total value, and post-transaction holdings). There is no accompanying guidance, trial update, contract, or regulatory action.
Market read
Traders may note the insider buy for sentiment, but the disclosed value is too small to be a standalone catalyst.
What to watch
No 10b5-1 plan is cited, but the filing does not provide intent, timing constraints, or whether other insiders are buying or selling around the same period.
Background
The article is an SEC Form 4 insider transaction disclosure for CTT Pharmaceutical Holdings, Inc. (CTTH).
Ticker impact
CTTH CEO filed a Form 4 open-market purchase of 1,800 shares at $0.0620/share on 2026-08-14, totaling $111.60.
Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment.
The filing is primary-source and same-day, but the transaction size ($111.60) is very small relative to typical market impact, and there is no 10b5-1 plan disclosed.
Market effects
Minimal sector read-through; this is a routine insider transaction with no operational or regulatory catalyst disclosed.
None indicated.
None indicated.
Counterpoint
The buy is extremely small and may reflect liquidity management or routine portfolio activity rather than a strong forward signal.
Key entities
- issuerCTT Pharmaceutical Holdings, Inc.
Subject of the Form 4 insider transaction; CEO purchased 1,800 shares at $0.0620/share.
- insiderCTTH CEO
Officer who executed the open-market purchase; pre-arranged 10b5-1 plan: no.